Table 3 Clinical PET studies using [¹⁸F]AlF-NOTA-octreotide

[¹⁸F]AlF-NOTA-octreotide

 2019

First comparison with [⁶⁸Ga]Ga-DOTATATE in diffuse metastases of rectal NET

1

[¹⁸F]AlF-NOTA-octreotide was a promising clinical alternative for [⁶⁸Ga]Ga-DOTATATE and warrants further head-to-head evaluation

Pauwels et al. (2019)

 2019

Biodistribution, safety and dosimetry in healthy volunteers. Detection of neuroendocrine neoplasms (NENs) in patients

Healthy: 3

Patients: 22

[¹⁸F]AlF-NOTA-octreotide was well tolerated and provided superior imaging of well-differentiated NENs. Tumour-to-background ratios were significantly higher compared to [¹⁸F]FDG

Long et al. (2019)

 2020

Biodistribution, dosimetry and comparison with [⁶⁸Ga]Ga-DOTATATE in NETs

Healthy: 6

Patients: 6

[¹⁸F]AlF-NOTA-octreotide was safe and well tolerated. Lesion detection rate and tumour-to-background ratios were comparable to [⁶⁸Ga]Ga-DOTATATE

Pauwels et al. (2020)

 2020

Head-to-head comparison with [⁶⁸Ga]Ga-DOTATATE in patients with NENs

Healthy: 3

Patients: 8

[¹⁸F]AlF-NOTA-octreotide produces similar image quality and fine detection rate of lesions, especially in the liver, because of lower liver background uptake than [⁶⁸Ga]Ga-DOTATATE

Hou et al. (2020)